Harrow, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Harrow, Inc. (HROW) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $32.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-02
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-09-30 was $0.00.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-06-30 was $0.00.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-03-31 was $29.00K.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $32.14M, a 358.47% increase from fiscal 2024.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $7.01M, a 53.08% increase from fiscal 2023.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $4.58M.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $1.02M, a 11.89% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $32.14M 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $7.01M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $4.58M 10-K · filed 2026-03-02 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $29.00K 10-Q · filed 2016-11-14 | $29.00K derived: sum of 4 quarters · filed 2016-11-14 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $29.00K 10-Q · filed 2016-08-15 | $29.00K derived: sum of 3 quarters · filed 2016-08-15 | |
| 2016-03-31 | $29.00K 10-Q · filed 2016-05-12 | $29.00K derived: sum of 2 quarters · filed 2016-05-12 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $1.02M 10-K · filed 2016-03-23 | ||
| 2015-09-30 | $1.02M 10-Q · filed 2015-11-12 | |||
| 2014-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $516.89K derived: sum of 2 quarters · filed 2015-03-12 | $588.10K derived: sum of 3 quarters · filed 2015-03-12 | $1.16M 10-K · filed 2015-03-12 |
| 2014-09-30 | $491.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $563.10K derived: sum of 2 quarters · filed 2014-11-12 | $1.14M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $71.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | $644.11K 10-Q · filed 2014-08-13 | ||
| 2014-03-31 | $572.90K 10-Q · filed 2014-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |